Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment

Maecke, Helmut R; Reubi, Jean-Claude (2011). Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. Journal of nuclear medicine, 52(6), pp. 841-4. New York, N.Y.: Society of Nuclear Medicine 10.2967/jnumed.110.084236

Full text not available from this repository. (Request a copy)

Radiolabeled peptides have been an important class of compounds in radiopharmaceutical sciences and nuclear medicine for more than 20 years. Despite strong research efforts, only somatostatin-based radiopeptides have a real impact on patient care, diagnostically and therapeutically. [(111)In-diethylenetriaminepentaacetic acid(0)]octreotide is commercially available for imaging. Imaging was highly improved by the introduction of PET radionuclides such as (68)Ga, (64)Cu, and (18)F. Two peptides are successfully used in targeted radionuclide therapy when bound to DOTA and labeled with (90)Y and (177)Lu.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Service Sector > Institute of Pathology

UniBE Contributor:

Reubi-Kattenbusch, Jean-Claude

Subjects:

500 Science > 570 Life sciences; biology
600 Technology > 610 Medicine & health

ISSN:

0161-5505

Publisher:

Society of Nuclear Medicine

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:18

Last Modified:

14 Oct 2019 16:32

Publisher DOI:

10.2967/jnumed.110.084236

PubMed ID:

21571797

Web of Science ID:

000291030000010

URI:

https://boris.unibe.ch/id/eprint/5557 (FactScience: 210311)

Actions (login required)

Edit item Edit item
Provide Feedback